Get the Stockscreener App
2.64
4.76%
0.12
After Hours:
2.66
0.02
+0.76%
Kiora Pharmaceuticals Inc stock is traded at $2.64, with a volume of 44,220.
It is up +4.76% in the last 24 hours and up +4.76% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$2.52
Open:
$2.53
24h Volume:
44,220
Relative Volume:
0.09
Market Cap:
$11.70M
Revenue:
$20,000
Net Income/Loss:
$-10.84M
P/E Ratio:
-0.9477
EPS:
-2.7857
Net Cash Flow:
$-10.07M
1W Performance:
-1.86%
1M Performance:
+4.76%
6M Performance:
+46.67%
1Y Performance:
-15.33%
1-Day Range:
$2.53
$2.70
1-Week Range:
$2.47
$2.72
52-Week Range:
$1.7645
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
858-224-9600
Address
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.64 | 11.12M | 20,000 | -10.84M | -10.07M | -2.7857 |
VRTX
Vertex Pharmaceuticals Inc
|
430.44 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.76 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.25 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.48 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
308.74 | 30.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
Kiora Pharmaceuticals (NASDAQ: KPRX) registers 11.8M resale shares - Stock Titan
Nantahala reports 9.99% stake in Kiora Pharmaceuticals (KPRX) - Stock Titan
Alyeska files 13G for Kiora (NASDAQ: KPRX) reporting 9.99% stake - Stock Titan
Nantahala holds 148,736 shares in Kiora Pharmaceuticals (KPRX) as 3.388% stake - Stock Titan
KPRX Stock Price, Quote & Chart | KIORA PHARMACEUTICALS INC (NASDAQ:KPRX) - ChartMill
TradingKey - TradingKey
Number of shareholders of Kiora Pharmaceuticals, Inc. – NASDAQ:KPRX - TradingView
EDGAR Filing Documents for 0001372514-23-000110 - SEC.gov
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora (NASDAQ: KPRX) details Q1 2026 results and cash runway to 2028 - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) reports Q1 loss but sees cash runway into late 2028 - Stock Titan
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile
Kiora says cash lasts into late 2028 as retinal studies advance - Stock Titan
Is Kiora Pharmaceuticals (KPRX) stock hiding in plain sight? (Risk Aversion) 2026-05-07Take Profit Levels - newser.com
Kiora Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
[ARS] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
KPRX Kiora Pharmaceuticals reports far wider Q4 2025 loss than estimates, shares hold flat in today’s trading. - newser.com
Kiora Pharmaceuticals (NASDAQ: KPRX) details 2026 director, pay and equity plan votes - Stock Titan
KPHMW SEC FilingsKiora Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) Industry Outlook | Q4 2025: Earnings UnderperformRevision Downgrade - Cổng thông tin điện tử tỉnh Lào Cai
KPRX Kiora Pharmaceuticals posts far wider Q4 2025 loss than estimates, shares dip nearly 2 percent today.Cycle Outlook - Cổng thông tin điện tử tỉnh Tây Ninh
Eric J. Daniels to Resign as Kiora Chief Development Officer Effective April 17, 2026 - TradingView
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway - TMX Newsfile
Perceptive Fund (RLAY) reports 9.99% ownership — 438,471 shares - Stock Titan
Breakouts Watch: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Action & Advanced Technical Signal Analysis - baoquankhu1.vn
Trend Recap: Will Kiora Pharmaceuticals Inc outperform its industry peers2026 Sentiment & Daily Profit Maximizing Tips - baoquankhu1.vn
What accelerates growth of Kiora Pharmaceuticals (KPRX) Stock | Price at $2.39, Down 3.24%Attention Driven Stocks - Newser
Profit Review: Is Kiora Pharmaceuticals Inc a cyclical or defensive stock2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
KPRX Technical Analysis & ETF Price Forecast - Intellectia AI
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
KPRX Faces Tumultuous Trading: Strategic Moves Amid Market Fluctuations - timothysykes.com
Kiora Pharmaceuticals Surges 23.5% Intraday – What's Fueling the Rally? - Bitget
KiORa Pharmaceuticals (KPRX) Stock: Jumps 24% After $24M Private Placement Deal - parameter.io
Kiora Pharmaceuticals closes $24M private placement By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges - StocksToTrade
Kiora Pharmaceuticals Inc. Poised for Strategic Expansion Amid Market Challenges - timothysykes.com
According to the latest filings disclosed by the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Kiora Pharmaceuticals (stock code: KPRX) plans to privately place 438,471 shares of its common stock to specific investors. - Bitget
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing - TipRanks
Kiora Pharmaceuticals IncEnters Securities Purchase Agreement On April 3, 2026SEC Filing - TradingView
Kiora Pharmaceuticals closes $24M private placement - Investing.com
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors - TMX Newsfile
Two biotech investors back Kiora with $5M now, $19M more later - Stock Titan
Kiora Pharmaceuticals Raises $5 Million in Private Placement With $19 Million Warrant UpsideTradingView - TradingView - Alle Märkte im Blick
Kiora (NASDAQ: KPRX) secures up to $24M in milestone-based private placement - Stock Titan
Kiora Pharmaceuticals chief development officer to depart By Investing.com - Investing.com India
Critical Outcome Technologies (OTCMKTS:COTQF) and Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Survey - Defense World
Kiora Pharmaceuticals Announces Chief Development Officer Resignation - TipRanks
Kiora Pharmaceuticals chief development officer to depart - Investing.com
Kiora Pharmaceuticals (KPRX) CFO uses 929 shares to cover taxes - Stock Titan
Kiora (NASDAQ: KPRX) executive uses 929 shares to satisfy tax withholding - Stock Titan
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):